Supernus Pharmaceuticals Enters Asset Purchase Agreement With Navitor On April 1, 2026; To Buy Assets Related To NV-5138 Or SPN-820, Including IP And Inventory; Purchase Price Includes Phase 2b Study And Milestone Payments Up To $350M; Agreement Includes Five-year Non-Compete And Non-Solicitation Covenant